
Shade
Danish tech & design startup that has set out to revolutionize interior lighting.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor | €0.0 | round |
* | €200k | Seed | |
Total Funding | 000k |
USD | 2021 | 2022 | 2023 |
---|---|---|---|
Revenues | 0000 | 0000 | 0000 |
% growth | - | - | (33 %) |
EBITDA | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Shade is a medical technology company focused on providing precise ultraviolet (UV) radiation monitoring solutions. The company was founded by Emmanuel Dumont, who serves as the CEO. Dumont's background is in Biomedical Engineering, holding a PhD from Columbia University where he researched protein degradation. His prior experience includes leading an NGO focused on health and energy in sub-Saharan Africa and two years in investment banking. The inspiration for Shade came from the realization that guesswork and standard sunscreens are insufficient for individuals with light-sensitive conditions, such as lupus, for whom UV overexposure can have severe health consequences.
The company's core product is a clinical-grade wearable sensor designed to accurately measure a user's cumulative UV exposure. This Oreo-sized device is worn on the body and pairs with a mobile application. The system provides users with real-time data and smart notifications to alert them as they approach their daily UV limit, allowing them to manage their sun exposure proactively. This addresses a significant challenge for patients who often avoid going outdoors due to the fear of accidental overexposure. The technology is positioned as being significantly more accurate than other UV sensors on the market.
Shade operates in the health-tech and medical device market, targeting individuals with photosensitive medical conditions like lupus and those at high risk for skin cancer. The business model appears to be direct-to-consumer sales of the wearable device and accompanying app. The company places a strong emphasis on clinical validation to build trust within the medical community. Shade has engaged in clinical trials with academic partners, including a significant trial on skin cancer with Weill Cornell Medicine, and has received funding from government agencies like the National Institutes of Health (NIH) National Cancer Institute and the National Science Foundation. Keywords: UV sensor, medical wearable, ultraviolet radiation, photosensitivity, lupus management, skin cancer prevention, Emmanuel Dumont, clinical-grade sensor, wearable technology, health tech, sun exposure tracking, personal health device, Cornell Tech, NIH funding, medical device, UV monitoring, digital health, patient monitoring, dermatology tech, photomedicine